Subvenite is a drug owned by Owp Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 29, 2040. Details of Subvenite's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11596634 | NA |
May, 2040
(14 years from now) | Active |
| US11612566 | NA |
May, 2040
(14 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Subvenite is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Subvenite's family patents as well as insights into ongoing legal events on those patents.
Subvenite's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Subvenite's generic launch date based on the expiry of its last outstanding patent is estimated to be May 29, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Subvenite Generic API suppliers:
Lamotrigine is the generic name for the brand Subvenite. 40 different companies have already filed for the generic of Subvenite, with Ph Health having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Subvenite's generic
Alternative Brands for Subvenite
There are several other brand drugs using the same active ingredient (Lamotrigine) as Subvenite. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Glaxosmithkline Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lamotrigine, Subvenite's active ingredient. Check the complete list of approved generic manufacturers for Subvenite
About Subvenite
Subvenite is a drug owned by Owp Pharmaceuticals Inc. Subvenite uses Lamotrigine as an active ingredient. Subvenite was launched by Owp Pharms in 2025.
Approval Date:
Subvenite was approved by FDA for market use on 16 September, 2025.
Active Ingredient:
Subvenite uses Lamotrigine as the active ingredient. Check out other Drugs and Companies using Lamotrigine ingredient
Dosage:
Subvenite is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML | SUSPENSION | Prescription | ORAL |